Comparative effects of liraglutide doses with and without exercise on glycemic control and lipid profiles: A Randomized Controlled Trial.

Abstract

Background: Liraglutide, a GLP-1 receptor agonist, is widely used to manage type 2 diabetes and obesity, showing potential benefits in improving glycemic control and lipid profiles, yet its effects across different doses and combined with exercise remain underexplored. This study seeks to determine the effects of three different doses of liraglutide, both with and without exercise, on blood glucose levels and lipid profiles in individuals with varying degrees of diabetes and metabolic risk.

Methodology: This three-arm randomized controlled trial at Isra University Hospital, Hyderabad, assessed the effects of varying doses of Liraglutide (Saxenda) on Glycated Hemoglobin (HbA1c) levels and lipid profiles over six months. Sixty participants aged 20-60 were randomly assigned to receive different doses of Liraglutide, with or without an exercise regimen.

Results: In Group A, Subgroup (i) exhibited a non-significant reduction in HbA1c from 4.85±1.35 to 4.77±1.2 after six months (p>0.05). However, Subgroup (ii) showed a significant reduction (p<0.05) in HbA1c levels after six months. Similarly, Groups B and C also demonstrated significant reductions in HbA1c after three months of intervention, with continued improvements over six months.

Conclusion: Liraglutide demonstrates significant potential as a therapeutic option for improving both glycemic control and lipid profiles. The study suggests that liraglutide has cardiovascular protective effects that extend beyond the reduction of LDL-C, highlighting its broader clinical benefits.